Proteogenomics Market (2026-2036)

The growth of this market is mainly driven by the growing use of combined genomic and proteomic data to identify and validate drug targets, the expansion of population-scale proteogenomic studies linking protein measurements to genetic and health data, the increasing application of proteogenomics in cancer research and precision oncology, and continuous advances in mass spectrometry and NGS-based proteomics technologies. In addition, the consolidation of proteomics and genomics capabilities within leading life science tools companies, the growth of single-cell and spatial multiomics, and the use of artificial intelligence (AI) to integrate and interpret multiomic datasets are further supporting the growth of this market.

The Proteogenomics Market, also referred to as the integrated proteomics and genomics market, protein-genome multiomics market, or proteogenomic analysis market, comprises the instruments, consumables and reagents, software, and services used to generate, integrate, and interpret proteomic and genomic data from the same samples or individuals. Proteogenomics combines DNA and RNA sequencing with protein measurement to understand how genetic variation, mutations, and gene expression are translated into protein abundance, protein variants, and post-translational modifications. The market includes mass spectrometry systems and NGS platforms used in proteogenomic studies; affinity proteomics assays with NGS readouts, such as proximity extension, aptamer-based, and NULISA assays; sample preparation, enrichment, and library preparation reagents; single-cell and spatial multiomics platforms that measure proteins and RNA together; bioinformatics software for building sample-specific protein databases, identifying variant peptides, and integrating multiomic data; and proteogenomic analysis services. The market ecosystem extends from technology providers to research consortia, biobanks, pharmaceutical and biotechnology companies, contract research organizations, and academic and clinical research centers.

The market is experiencing strong growth as researchers recognize that genomic data alone cannot fully explain disease biology or predict drug response. Most drugs act on proteins, and protein levels often do not correlate directly with gene or RNA expression because of translational control, protein degradation, and post-translational modification. By measuring proteins in the context of genetic data, proteogenomics enables researchers to identify protein quantitative trait loci (pQTLs), establish causal links between genes, proteins, and disease, discover tumor-specific protein variants and neoantigens, and prioritize drug targets with stronger genetic evidence. These capabilities are making proteogenomics an important approach in drug discovery, cancer research, and precision medicine.

Large research programs are demonstrating the value of proteogenomics and creating demand for technologies and services. The Clinical Proteomic Tumor Analysis Consortium (CPTAC) of the U.S. National Cancer Institute released a pan-cancer proteogenomic resource covering more than 1,000 tumors across 10 cancer types, combining genomic, proteomic, imaging, and clinical data that are publicly available through the NCI Cancer Research Data Commons. In January 2025, UK Biobank selected the Olink Explore platform of Thermo Fisher Scientific for the UK Biobank Pharma Proteomics Project, a collaboration with 14 biopharmaceutical companies that is measuring more than 5,400 proteins in up to 600,000 samples with linked genetic and health data, with staggered data releases beginning in 2026 and the full dataset expected in 2027. A 2023 UK Biobank pilot that analyzed more than 54,000 samples, published in Nature, has been cited more than 400 times, illustrating the scientific impact of combining protein and genetic data at scale. Illumina Protein Prep measures up to 9,500 unique human protein targets in a single experiment with an NGS readout, and has been used by Genomics England to profile more than 7,800 rare disease participants of the 100,000 Genomes Project, allowing protein data to be analyzed alongside whole-genome sequences. In Singapore, the PRECISE-SG100K population health study is generating large-scale proteomic data alongside genomic data, supported by a strategic collaboration between Thermo Fisher Scientific and Precision Health Research, Singapore, using the Orbitrap Astral mass spectrometer, while Seer and Nanyang Technological University are presenting early PRECISE-SG100K proteomics findings at HUPO 2026.

The competitive landscape has changed significantly as genomics and analytical instrument companies build integrated proteomics and multiomics portfolios. Thermo Fisher Scientific acquired Olink in July 2024, combining NGS-based affinity proteomics with its Orbitrap mass spectrometry portfolio, and introduced the Orbitrap Tribrid Apex and Orbitrap Excedion mass spectrometers at the American Society for Mass Spectrometry (ASMS) conference in June 2026. In January 2026, Illumina completed the acquisition of SomaLogic from Standard BioTools for USD 350 million in cash at closing, plus up to USD 75 million in near-term milestones and performance-based royalties, combining the SomaScan aptamer-based proteomics assay with the Illumina NGS ecosystem, DRAGEN software, and Illumina Connected Multiomics, and expects SomaLogic to contribute 1.5% to 2.0% to its fiscal 2026 revenue. Bruker has built a multiomics portfolio through the acquisitions of PreOmics and Biognosys in proteomics and biocrates in metabolomics in June 2025, describing multiomics as the cornerstone for the future of life sciences. Waters completed its combination with the Biosciences and Diagnostic Solutions businesses of BD in February 2026, creating a Waters Biosciences division that includes single-cell multiomics.

Specialized technology providers are also contributing to market growth. Alamar Biosciences, which completed its initial public offering in April 2026, reported Q2 2026 revenue of USD 29.4 million, up 82% year over year, for its NULISA proteomics platform with an NGS readout. Seer offers the Proteograph product suite for deep plasma proteomics by mass spectrometry, which was used in an independent study published in Nature Genetics on plasma protein levels and disease risk in British South Asians. In single-cell and spatial biology, platforms that measure proteins and RNA in the same cells are enabling proteogenomic analysis at cellular resolution.

At the same time, the market faces challenges related to the complexity of integrating data from different technologies, the high cost of large-scale studies, and constraints on academic and government research funding. Seer reported that its Q2 2026 revenue declined 23% to USD 3.1 million due to pressure on academic and government funding and longer sales cycles. As a result, providers that can offer scalable workflows, integrated software, and strong evidence of biological and clinical value are expected to capture the largest share of growth over the forecast period.